Abstract Number: 061 • 2023 Pediatric Rheumatology Symposium
Variation in Treatment Approaches to IVIG- Refractory Kawasaki Disease (KD) Among Pediatric Rheumatologists: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) Treatment of Refractory KD Survey
Background/Purpose: Kawasaki disease (KD) is the leading cause of acquired heart disease in children in North America. Initial treatment with IVIG has significantly reduced the…Abstract Number: 103 • 2023 Pediatric Rheumatology Symposium
Clinical, Serologic, and Imaging Findings of Rhupus Syndrome in the Pediatric Population: A Systematic Literature Review
Background/Purpose: Pediatric Rhupus syndrome is a complex autoimmune disease characterized by overlapping clinical and immunological features of Juvenile Idiopathic Arthritis (JIA) and juvenile Systemic Lupus…Abstract Number: 033 • 2023 Pediatric Rheumatology Symposium
Kawasaki Disease (KD) Criteria Fulfillment and Associated Outcomes in Multisystem Inflammatory Syndrome in Children (MIS-C)
Background/Purpose: Multisystem inflammatory syndrome in children (MIS-C) is a hyperinflammatory illness associated with SARS-CoV-2 infection and has overlapping features with Kawasaki Disease (KD). The objective…Abstract Number: 062 • 2023 Pediatric Rheumatology Symposium
Assessment of Barriers and Facilitators in Implementation of the Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans
Background/Purpose: Since 2010, the Childhood Arthritis and Rheumatology Research Alliance (CARRA) has developed 12 consensus treatment plans (CTP) with the aim of reducing treatment variability…Abstract Number: 106 • 2023 Pediatric Rheumatology Symposium
Caregivers’ Perspectives on Barriers to Care in Juvenile Localized and Systemic Scleroderma
Background/Purpose: Juvenile localized scleroderma (LS) and systemic sclerosis (SSc) are rare rheumatic diseases often associated with severe morbidities. Delays in diagnosis are common, putting children…Abstract Number: 036 • 2023 Pediatric Rheumatology Symposium
Predictive Factors of Long-lasting Remission Following Anakinra Withdrawal in Patients with Systemic Juvenile Idiopathic Arthritis After Achievement of Clinical Inactive Disease
Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) is a rare autoinflammatory disease of unknown etiology. Several uncontrolled studies showed that early treatment with anakinra is associated…Abstract Number: 063 • 2023 Pediatric Rheumatology Symposium
JAK Inhibition in down Syndrome Associated Arthritis (DA) – Our Experience to Date with Tofacitinib in 5 Patients
Background/Purpose: Down syndrome associated arthritis (DA) is a challenging form of inflammatory arthritis that typically is more erosive and has a greater requirement for biologic…Abstract Number: 107 • 2023 Pediatric Rheumatology Symposium
Validation of Serious Adverse Event Reporting in a Multicenter Registry
Background/Purpose: Children with rheumatic disease frequently require management with immune suppressing medications. The benefits of these interventions often outweigh the risks, however serious adverse events…Abstract Number: 0109 • ACR Convergence 2022
The Impact of Marginalization on Health Outcomes in Childhood-onset Systemic Lupus Erythematosus
Background/Purpose: Adolescents with childhood-onset systemic lupus erythematosus (cSLE) face challenges in managing their disease and mental health. There is increasing evidence that community-level social and…Abstract Number: 0851 • ACR Convergence 2022
Responsiveness of Patient-Reported Physical Function Measures in Juvenile Arthritis
Background/Purpose: The ACR Pediatric Criteria (ACR Pedi) contains a core set of outcome variables, including a measure of functional ability, to evaluate improvement over time…Abstract Number: 0942 • ACR Convergence 2022
Evaluation of Ovarian Reserve Using Anti-Mullerian Hormone Levels in Adolescents with Systemic Rheumatic Disease Compared to Healthy Controls
Background/Purpose: Medical evidence suggests decreased ovarian reserve in women with rheumatic disease; however, studies in adolescents are lacking. Anti-Mullerian hormone (AMH) levels in serum are…Abstract Number: 1364 • ACR Convergence 2022
Diffuse Juvenile Systemic Sclerosis Patients Show Distinct Organ Involvement and Have More Severe Disease in the Largest jSSc Cohort of the World. Results from the the Juvenile Scleroderma Inception Cohort
Background/Purpose: Juvenile systemic sclerosis (jSSc) is an orphan disease with a prevalence of 3 in 1 000 000 children. In adult patients there are significant…Abstract Number: 1384 • ACR Convergence 2022
Echocardiographic Screening in Childhood Onset Systemic Lupus Erythematosus
Background/Purpose: Childhood onset SLE is an autoantibody mediated, multisystem disease which can include cardiac manifestations. Because cardiac involvement can develop insidiously, an earlier review from…Abstract Number: 1937 • ACR Convergence 2022
Adult Rheumatologists’ Knowledge, Comfort Level, and Perceived Barriers in Supporting Newly Transitioned Youth with Chronic Rheumatic Diseases in Canada
Background/Purpose: Transitioning from pediatric to adult rheumatology care around age 18 is an important and often challenging period in patients' lives. Differences between adult and…Abstract Number: 2244 • ACR Convergence 2022
Salient Coping Strategies Among Youth with Chronic Musculoskeletal Pain
Background/Purpose: Youth with chronic musculoskeletal pain (CMP) learn pain-coping strategies and build resilience through cognitive behavioral therapy (CBT). In order to expand therapeutic options for…
- « Previous Page
- 1
- …
- 21
- 22
- 23
- 24
- 25
- …
- 52
- Next Page »